Please login to the form below

Not currently logged in
Email:
Password:

LJPC-501

This page shows the latest LJPC-501 news and features for those working in and with pharma, biotech and healthcare.

La Jolla plans filing on back of blood pressure trial data

La Jolla plans filing on back of blood pressure trial data

The ATHOS-3 study found that LJPC-501, a synthetic formulation of natural peptide called angiotensin II that regulates blood pressure, hit its primary endpoint of raising blood pressure in patients ... All told, 70% of the LJPC-501-treated group in

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics